Page 211 - EJMO-9-1

Eurasian Journal of Medicine and
Oncology
Cost-effectiveness of nivolumab+chemo for gastric/GEJ cancer

doi: 10.1002/cncr.25030 Ther. 2020;37(5):2116-2126.
29. Wan N, Zhang TT, Hua SH, et al. Cost-effectiveness doi: 10.1007/s12325-020-01292-3
analysis of pembrolizumab plus chemotherapy with PD-L1 33. Pongchaiyakul C, Nanagara R, Songpatanasilp T,
test for the first-line treatment of NSCLC. Cancer Med. Unnanuntana A. Cost-effectiveness of denosumab for high-
2020;9(5):1683-1693.
risk postmenopausal women with osteoporosis in Thailand.
doi: 10.1002/cam4.2793 J Med Econ. 2020;23(7):776-785.
30. Zhang PF, Xie D, Li Q. Cost-effectiveness analysis of doi: 10.1080/13696998.2020.1730381
nivolumab in the second-line treatment for advanced
esophageal squamous cell carcinoma. Future Oncol Lond 34. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health
Engl. 2020;16(17):1189-1198. state utilities for non small cell lung cancer. Health Qual Life
Outcomes. 2008;6:84.
doi: 10.2217/fon-2019-0821
doi: 10.1186/1477-7525-6-84
31. Chouaid C, Bensimon L, Clay E, et al. Cost-effectiveness
analysis of pembrolizumab versus standard-of-care 35. Ward MC, Shah C, Adelstein DJ, et al. Cost-effectiveness of
chemotherapy for first-line treatment of PD-L1 positive nivolumab for recurrent or metastatic head and neck cancer.
(>50%) metastatic squamous and non-squamous non- Oral Oncol. 2017;74:49-55.
small cell lung cancer in France. Lung Cancer Amst Neth. doi: 10.1016/j.oraloncology.2017.09.017
2019;127:44-52.
36. Lam SW, Wai M, Lau JE, McNamara M, Earl M, Udeh B.
doi: 10.1016/j.lungcan.2018.11.008 Cost-effectiveness analysis of second-line chemotherapy
agents for advanced gastric cancer. Pharmacotherapy.
32. Ding D, Hu H, Liao M, et al. Cost-effectiveness analysis of
atezolizumab plus chemotherapy in the first-line treatment 2017;37(1):94-103.
of metastatic non-squamous non-small cell lung cancer. Adv doi: 10.1002/phar.1870

Volume 9 Issue 1 (2025) 203 doi: 10.36922/ejmo.7075